non-familial hypercholesterolaemia with ASCVD
Cardiovascular · 2018–2020
4decisions
2medicines
2carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| alirocumab Treatment of non-familial hypercholesterolaemia (non-FH) in patients with atherosclerotic cardiovascular disease (ASCVD) and additional high-risk factors, to… | Mar 2020 | Recommended with restriction | none received |
| evolocumab Treatment of non-familial hypercholesterolaemia in patients with atherosclerotic cardiovascular disease (ASCVD) who have additional risk factors, and extension… | Jul 2019 | Deferred | 2 individuals |
| evolocumab Treatment of non-familial hypercholesterolaemia in patients with atherosclerotic cardiovascular disease and additional high-risk factors, and familial… | Nov 2019 | Recommended with restriction | none received |
| evolocumab Treatment of non-familial hypercholesterolaemia with atherosclerotic cardiovascular disease in patients who have not achieved target LDL levels despite… | Jul 2018 | Not recommended | input received |
What the PBS pays
$63M in government benefit over 2024–25, across 176,912 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| evolocumab | $63.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.